Status:
COMPLETED
Systemic Immunosuppressive Therapy for Eye Diseases (SITE) Cohort Study
Lead Sponsor:
National Eye Institute (NEI)
Conditions:
Uveitis
Cancer
Eligibility:
All Genders
Brief Summary
This study will evaluate whether therapy that suppresses the immune system given to treat inflammatory diseases of the eye is associated with a greater risk of death and of cancer. Inflammatory diseas...
Detailed Description
BACKGROUND: Ocular inflammatory diseases, including uveitis, scleritis, and mucous membrane pemphigoid, are major blinding eye diseases. For some patients, corticosteroid therapy is insufficient to c...
Eligibility Criteria
Inclusion
- INCLUSION CRITERIA: Patients with the following diagnoses will be included:
- Anterior uveitis;
- Intermediate uveitis;
- Posterior uveitis or panuveitis;
- Scleritis;
- Mucous membrane pemphigoid;
- Other non-infectious ocular inflammatory disease.
- EXCLUSION CRITERIA:
- No ocular inflammatory disease;
- Infectious ocular inflammatory disease (e.g. toxoplasmic retinitis, endophthalmitis, viral retinitis), unless the infectious uveitis followed treatment for a non-infectious ocular inflammatory disease.
Exclusion
Key Trial Info
Start Date :
June 16 2005
Trial Type :
OBSERVATIONAL
End Date :
April 21 2008
Estimated Enrollment :
6300 Patients enrolled
Trial Details
Trial ID
NCT00116090
Start Date
June 16 2005
End Date
April 21 2008
Last Update
July 2 2017
Active Locations (4)
Enter a location and click search to find clinical trials sorted by distance.
1
Johns Hopkins University
Baltimore, Maryland, United States, 21205
2
National Institutes of Health Clinical Center, 9000 Rockville Pike
Bethesda, Maryland, United States, 20892
3
Massachusetts Eye and Ear Infirmary
Boston, Massachusetts, United States, 02114-3096
4
Oregon Health Sciences University
Portland, Oregon, United States, 97201-3098